Lilly’s Insulin Cost Cutting Plan: Replacing Rebates With Cost Sharing Help At Point Of Sale
Biden Administration praises Lilly for latest moves to improve affordability of insulin in private market and calls for other sponsors to follow suit. Lilly’s plan is also tactical, as manufacturers of highly-rebated drugs with serial price hikes face an increased rebate liability in Medicaid next year.
You may also be interested in...
‘Why Stop At Insulin?’ Senate Democrats Want More List Price Moves From Pharma
Pharma was unable to punt all the drug pricing blame to pharmacy benefits managers at the 10 May Senate HELP hearing on affordable insulin, though the PBM-focused fury was more bipartisan.
Senate HELP Panel’s Confounded Markup Points To Challenges Ahead For Chairman Sanders
Session on PBM and generic legislation brought to a halt by Republican objections to amendments targeting FDA disclosure of inactive ingredient concentrations in brands, method-of-use patents, and using REMS to extend patent protection.
Bipartisan Senate Finance Framework Takes ‘Measured’ Aim At PBMs
Framework from Sens. Wyden and Crapo, looks like it would change, but not eliminate, the rebate system and gets an initial thumbs up from both the brand and generic drug lobbies.